Silvia Vega-Rubin-De-Celis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Silvia Vega-Rubin-De-Celis has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Samuel Peña-Llopis
Translational Genomics, Department of Ophthalmology, University Hospital Essen, 45147 Essen, Germany
3 shared publications Verena Jendrossek
University Hospital Essen
3 shared publications- Verena Jendrossek
Institute of Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany
3 shared publications - Alvaro Fernandez-Fernandez
Departamento de Bioquímica y Biología Molecular, Universidad de Oviedo, 33006 Oviedo, Spain
2 shared publications Christoph Thomssen
Department of Gynaecology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
2 shared publicationsJetsy Montero-Vergara
Institute of Cell Biology (Cancer Research), University Hospital Essen, Essen, Germany
2 shared publications
Latest Publications
- Open Access
- 3 August 2025
- Published by Taylor & Francis in Autophagy
- Vol. 21 (12) , 3324-3343
Autophagy suppression via SRC induction represents a therapeutic vulnerability for BAP1 -mutant cancers
BAP1 is a tumor suppressor and epigenetic modifier that is frequently mutated in cancer, leading to increased aggressiveness and metastasis, as well as poor patient survival. Unfortunately, there are currently no specific therapies for metastatic tumors harboring BAP1 mutations. In this study, we have identified a new targetable BAP1-associated autophagic vulnerability. We demonstrate that BAP1 transcriptionally regulates the proto-oncogene SRC, a non-receptor tyrosine kinase. SRC then binds to, phosphorylates, and inactivates BECN1 (Beclin 1), an essential autophagy protein. This inhibits autophagy in cells derived from various cancer types with BAP1 mutations. Treatment of these cells with SRC inhibitors (such as dasatinib, bosutinib and saracatinib) and autophagy-inducing drugs (such as Tat-BECN1, SW076956 and SW063058) demonstrated a synergistic interaction between these compounds both in vitro and in ovo using a chick Chorioallantoic Membrane (CAM) assay. Furthermore, ex vivo studies employing patient-derived tumor organoids (PDTOs) of uveal melanoma (UM) and clear-cell renal cell carcinoma (ccRCC) as preclinical models have substantiated the synergism of these drugs, preferentially in the context of BAP1 loss. Our findings elucidate a novel BAP1-SRC-BECN1-autophagy regulatory axis that can be exploited therapeutically in precision oncology through the combination of SRC inhibitors and autophagy inducers, contingent upon patient stratification for BAP1 loss.Significance: Deadly cancers with BAP1 mutations suppress autophagy by phosphorylating the autophagy regulator BECN1 via the proto-oncogene SRC. Treatment with SRC inhibitors and autophagy inducers exhibited synergism in vitro, in ovo and in patient-derived tumor organoids with BAP1 loss, paving the way for treating BAP1-deficient cancers with autophagy inducers and kinase inhibitors.
- 3 August 2025
- Published by Taylor & Francis in Autophagy
- Vol. 21 (12) , 3324-3343
Open AccessAutophagy suppression via SRC induction represents a therapeutic vulnerability for BAP1 -mutant cancers
BAP1 is a tumor suppressor and epigenetic modifier that is frequently mutated in cancer, leading to increased aggressiveness and metastasis, as well as poor patient survival. Unfortunately, there are currently no specific therapies for metastatic tumors harboring BAP1 mutations. In this study, we have identified a new targetable BAP1-associated autophagic vulnerability. We demonstrate that BAP1 transcriptionally regulates the proto-oncogene SRC, a non-receptor tyrosine kinase. SRC then binds to, phosphorylates, and inactivates BECN1 (Beclin 1), an essential autophagy protein. This inhibits autophagy in cells derived from various cancer types with BAP1 mutations. Treatment of these cells with SRC inhibitors (such as dasatinib, bosutinib and saracatinib) and autophagy-inducing drugs (such as Tat-BECN1, SW076956 and SW063058) demonstrated a synergistic interaction between these compounds both in vitro and in ovo using a chick Chorioallantoic Membrane (CAM) assay. Furthermore, ex vivo studies employing patient-derived tumor organoids (PDTOs) of uveal melanoma (UM) and clear-cell renal cell carcinoma (ccRCC) as preclinical models have substantiated the synergism of these drugs, preferentially in the context of BAP1 loss. Our findings elucidate a novel BAP1-SRC-BECN1-autophagy regulatory axis that can be exploited therapeutically in precision oncology through the combination of SRC inhibitors and autophagy inducers, contingent upon patient stratification for BAP1 loss.Significance: Deadly cancers with BAP1 mutations suppress autophagy by phosphorylating the autophagy regulator BECN1 via the proto-oncogene SRC. Treatment with SRC inhibitors and autophagy inducers exhibited synergism in vitro, in ovo and in patient-derived tumor organoids with BAP1 loss, paving the way for treating BAP1-deficient cancers with autophagy inducers and kinase inhibitors.
- Open Access
- 6 March 2024
- Published by Taylor & Francis in Autophagy Reports
- Vol. 3 (1)
GRB2, a protein known for a long time with a new autophagy-regulating function
BECN1 (BCL2 interacting myosin like coiled protein) is a major regulator of autophagy and a haploinsufficient tumor suppressor. BECN1 binds to multiple proteins and it is part of at least two different class III phosphatidylinositol (PI) 3 Kinase (PI3KC3) complexes that regulate autophagy and endocytic trafficking through the biosynthesis of phosphatidylinositol-3-phosphate. BECN1 and the activity of the PI3KC3 are regulated by post-translational modifications and/or subcellular localization. We recently discovered that GRB2 (growth factor receptor bound protein 2), an adaptor protein of several tyrosine kinases, interacts with BECN1 and regulates autophagy.1
- 6 March 2024
- Published by Taylor & Francis in Autophagy Reports
- Vol. 3 (1)
Open AccessGRB2, a protein known for a long time with a new autophagy-regulating function
BECN1 (BCL2 interacting myosin like coiled protein) is a major regulator of autophagy and a haploinsufficient tumor suppressor. BECN1 binds to multiple proteins and it is part of at least two different class III phosphatidylinositol (PI) 3 Kinase (PI3KC3) complexes that regulate autophagy and endocytic trafficking through the biosynthesis of phosphatidylinositol-3-phosphate. BECN1 and the activity of the PI3KC3 are regulated by post-translational modifications and/or subcellular localization. We recently discovered that GRB2 (growth factor receptor bound protein 2), an adaptor protein of several tyrosine kinases, interacts with BECN1 and regulates autophagy.1
- Open Access
- 5 January 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (1) , 1-11
GRB2 is a BECN1 interacting protein that regulates autophagy
GRB2 is an adaptor protein of HER2 (and several other tyrosine kinases), which we identified as a novel BECN1 (Beclin 1) interacting partner. GRB2 co-immunoprecipitated with BECN1 in several breast cancer cell lines and regulates autophagy through a mechanism involving the modulation of the class III PI3Kinase VPS34 activity. In ovo studies in a CAM (Chicken Chorioallantoic Membrane) model indicated that GRB2 knockdown, as well as overexpression of GRB2 loss-of-function mutants (Y52A and S86A-R88A) compromised tumor growth. These differences in tumor growth correlated with differential autophagy activity, indicating that autophagy effects might be related to the effects on tumorigenesis. Our data highlight a novel function of GRB2 as a BECN1 binding protein and a regulator of autophagy.
- 5 January 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (1) , 1-11
Open AccessGRB2 is a BECN1 interacting protein that regulates autophagy
GRB2 is an adaptor protein of HER2 (and several other tyrosine kinases), which we identified as a novel BECN1 (Beclin 1) interacting partner. GRB2 co-immunoprecipitated with BECN1 in several breast cancer cell lines and regulates autophagy through a mechanism involving the modulation of the class III PI3Kinase VPS34 activity. In ovo studies in a CAM (Chicken Chorioallantoic Membrane) model indicated that GRB2 knockdown, as well as overexpression of GRB2 loss-of-function mutants (Y52A and S86A-R88A) compromised tumor growth. These differences in tumor growth correlated with differential autophagy activity, indicating that autophagy effects might be related to the effects on tumorigenesis. Our data highlight a novel function of GRB2 as a BECN1 binding protein and a regulator of autophagy.
- Open Access
- 27 June 2022
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 10, 891332
Beth Levine’s Legacy: From the Discovery of BECN1 to Therapies. A Mentees’ Perspective
With great sadness, the scientific community received the news of the loss of Beth Levine on 15 June 2020. Dr. Levine was a pioneer in the autophagy field and work in her lab led not only to a better understanding of the molecular mechanisms regulating the pathway, but also its implications in multiple physiological and pathological conditions, including its role in development, host defense, tumorigenesis, aging or metabolism. This review does not aim to provide a comprehensive view of autophagy, but rather an outline of some of the discoveries made by the group of Beth Levine, from the perspective of some of her own mentees, hoping to honor her legacy in science.
- 27 June 2022
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 10, 891332
Open AccessBeth Levine’s Legacy: From the Discovery of BECN1 to Therapies. A Mentees’ Perspective
With great sadness, the scientific community received the news of the loss of Beth Levine on 15 June 2020. Dr. Levine was a pioneer in the autophagy field and work in her lab led not only to a better understanding of the molecular mechanisms regulating the pathway, but also its implications in multiple physiological and pathological conditions, including its role in development, host defense, tumorigenesis, aging or metabolism. This review does not aim to provide a comprehensive view of autophagy, but rather an outline of some of the discoveries made by the group of Beth Levine, from the perspective of some of her own mentees, hoping to honor her legacy in science.
- Open Access
- 1 January 2022
- Published by Springer Nature
- Vol. 2445, 75-98
A Dual HiBiT-GFP-LC3 Lentiviral Reporter for Autophagy Flux Assessment
Autophagy is an intracellular degradation process that maintains the cellular homeostasis and it is regulated in multiple ways, both in health and disease. Assessment of autophagic flux in cells is an important approach for understanding the function of autophagy in biological contexts. Here, we describe a new tool for the qualitative and quantitative determination of autophagic flux using a dual lentiviral reporter system that generates a fusion HiBiT-GFP-LC3B protein suitable for generating stable cell lines.
- 1 January 2022
- Published by Springer Nature
- Vol. 2445, 75-98
Open AccessA Dual HiBiT-GFP-LC3 Lentiviral Reporter for Autophagy Flux Assessment
Autophagy is an intracellular degradation process that maintains the cellular homeostasis and it is regulated in multiple ways, both in health and disease. Assessment of autophagic flux in cells is an important approach for understanding the function of autophagy in biological contexts. Here, we describe a new tool for the qualitative and quantitative determination of autophagic flux using a dual lentiviral reporter system that generates a fusion HiBiT-GFP-LC3B protein suitable for generating stable cell lines.
- Open Access
- 1 January 2022
- Published by Springer Nature
- Vol. 2445, 255-272
Studying Autophagy In Vivo in the Mammary Gland and in Xenograft Samples
Autophagy is a dynamic process that can be monitored in multiple ways, both in vitro and in vivo. Studies in mice are a widely used tool to understand multiple diseases and conditions where autophagy plays a role, and therefore autophagic flux measurement in tissues of rodent models are of utmost importance. Here, we present some assays successfully used in determining the autophagy status in the mice mammary gland as well as in xenografts.
- 1 January 2022
- Published by Springer Nature
- Vol. 2445, 255-272
Open AccessStudying Autophagy In Vivo in the Mammary Gland and in Xenograft Samples
Autophagy is a dynamic process that can be monitored in multiple ways, both in vitro and in vivo. Studies in mice are a widely used tool to understand multiple diseases and conditions where autophagy plays a role, and therefore autophagic flux measurement in tissues of rodent models are of utmost importance. Here, we present some assays successfully used in determining the autophagy status in the mice mammary gland as well as in xenografts.
- Open Access
Metabolism of cancer cells commonly responds to irradiation by a transient early mitochondrial shutdown
- Open Access
A BAP1 synonymous mutation results in exon skipping, loss of function and worse patient prognosis
- Open Access
- 24 December 2020
- Published by Wiley in International Journal of Cancer
- Vol. 148 (8) , 1993-2009
Abrogating GPT2 in triple‐negative breast cancer inhibits tumor growth and promotes autophagy
Uncontrolled proliferation and altered metabolic reprogramming are hallmarks of cancer. Active glycolysis and glutaminolysis are characteristic features of these hallmarks and required for tumorigenesis. A fine balance between cancer metabolism and autophagy is a prerequisite of homeostasis within cancer cells. Here we show that glutamate pyruvate transaminase 2 (GPT2), which serves as a pivot between glycolysis and glutaminolysis, is highly upregulated in aggressive breast cancers, particularly the triple‐negative breast cancer subtype. Abrogation of this enzyme results in decreased tricarboxylic acid cycle intermediates, which promotes the rewiring of glucose carbon atoms and alterations in nutrient levels. Concordantly, loss of GPT2 results in an impairment of mechanistic target of rapamycin complex 1 activity as well as the induction of autophagy. Furthermore, in vivo xenograft studies have shown that autophagy induction correlates with decreased tumor growth and that markers of induced autophagy correlate with low GPT2 levels in patient samples. Taken together, these findings indicate that cancer cells have a close network between metabolic and nutrient sensing pathways necessary to sustain tumorigenesis and that aminotransferase reactions play an important role in maintaining this balance.
- 24 December 2020
- Published by Wiley in International Journal of Cancer
- Vol. 148 (8) , 1993-2009
Open AccessAbrogating GPT2 in triple‐negative breast cancer inhibits tumor growth and promotes autophagy
Uncontrolled proliferation and altered metabolic reprogramming are hallmarks of cancer. Active glycolysis and glutaminolysis are characteristic features of these hallmarks and required for tumorigenesis. A fine balance between cancer metabolism and autophagy is a prerequisite of homeostasis within cancer cells. Here we show that glutamate pyruvate transaminase 2 (GPT2), which serves as a pivot between glycolysis and glutaminolysis, is highly upregulated in aggressive breast cancers, particularly the triple‐negative breast cancer subtype. Abrogation of this enzyme results in decreased tricarboxylic acid cycle intermediates, which promotes the rewiring of glucose carbon atoms and alterations in nutrient levels. Concordantly, loss of GPT2 results in an impairment of mechanistic target of rapamycin complex 1 activity as well as the induction of autophagy. Furthermore, in vivo xenograft studies have shown that autophagy induction correlates with decreased tumor growth and that markers of induced autophagy correlate with low GPT2 levels in patient samples. Taken together, these findings indicate that cancer cells have a close network between metabolic and nutrient sensing pathways necessary to sustain tumorigenesis and that aminotransferase reactions play an important role in maintaining this balance.